Skip to main content

Jesus Castro Marrero

Jesús Castro is currently a Senior Postdoctoral Researcher linked to the Vall d'Hebron University Hospital Research Institute (VHIR) since 2000. In the last 20 years, Dr. Castro has dedicated themselves to basic research in autoimmune and rheumatic diseases with more than 50 publications and book chapters high impact He is currently the coordinator of the laboratory of postviral fatigue syndromes at the Vall d'Hebron Hospital (Barcelona, Spain).

Institutions of which they are part

Postdoctoral researcher
Rheumatology
Vall Hebron Institut de Recerca
Jesus Castro Marrero

Jesus Castro Marrero

Jesus Castro Marrero

Institutions of which they are part

Postdoctoral researcher
Rheumatology
Vall Hebron Institut de Recerca

Jesús Castro is currently a Senior Postdoctoral Researcher linked to the Vall d'Hebron University Hospital Research Institute (VHIR) since 2000. In the last 20 years, Dr. Castro has dedicated themselves to basic research in autoimmune and rheumatic diseases with more than 50 publications and book chapters high impact He is currently the coordinator of the laboratory of postviral fatigue syndromes at the Vall d'Hebron Hospital (Barcelona, Spain).

Jesus Castro earned his Postdoctoral Researcher Fellowship degree in Biochemistry and Molecular Biology program at the Valladolid University School of Medicine, Spain in 1999. Dr. Castro is currently a Senior Postdoctoral Research at the Vall d’Hebron Hospital Research Institute, University of Barcelona School of Medicine, Barcelona, Spain since 2002. In the past 20 years have been devoted to basic research of respiratory medicine, autoimmune and rheumatic conditions with over 50 high-impact factor publications and book chapters. He is currently the coordinator of the CFS/ME Research Laboratory at the Vall d'Hebron Hospital, in Barcelona, Spain. Dr. Castro is a member of the E.U. CFS/ME Research Collaborative Consortium Initiative (European Myalgic Encephalomyelitis NEtwork-EUROMENE). His current research is focused on the bioenergetic metabolism, mitochondrial dysfunction, and neuroimmune pathways linked to the immune response in CFS/ME, as well as finding useful biomarkers to aid in the diagnosis, treatment, and management of CFS/ME through clinical trials in order to improve prognosis and quality of life of CFS/ME patients.

Projects

Disfunción autonómica y ritmo circadiano en el Síndrome de Fatiga Crónica/Encefalomielitis Miálgica: nuevas herramientas diagnósticas y terapéuticas en la enfermedad

IP: Jesus Castro Marrero
Collaborators: José Alegre Martin
Funding agency: Instituto de Salud Carlos III
Funding: 87120
Reference: PI19/00629
Duration: 01/01/2020 - 30/06/2024

Development, dIagnostic and prevention of gender-related Somatic and mental COmorbitiEs in IRritable bowel syndrome In Europe (DISCOvERIE)

IP: Fco Javier Santos Vicente
Collaborators: Beatriz Lobo Alvarez, José Alegre Martin, Amanda Rodríguez Urrutia, Silvia Muñoz Caller, Carmen Alonso Cotoner, Jesus Castro Marrero, Natalia Rodriguez Santas, Ana Maria Gonzalez Castro, Marc Pigrau Pastor, Adoración Nieto Ruiz, Natalia Llonga Tejedor, Alejandro Henao Paez, Consuelo Cammarota
Funding agency: EUROPEAN COMMISSION
Funding: 1148684.84
Reference: DISCOVERIE_H2020-SC1-BHC_2019
Duration: 01/01/2020 - 31/05/2025

Sol·licitud per estada al Center for Enervating NeuroImmune Disease (CENID), a la Cornell University (Ithaca, NY) per dur a terme el projecte "Exosomas en la Encefalomielitis Miálgica/Síndrome de Fatiga Crónica: posible biomarcador diagnóstico y terapéu

IP: Jesus Castro Marrero
Collaborators: -
Funding agency: Ministerio de Educación, Cultura y Deporte
Funding: 16633
Reference: PRX17/00361
Duration: 01/05/2018 - 30/09/2018

European Network on Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (EUROMENE)

IP: Jesus Castro Marrero
Collaborators: José Alegre Martin
Funding agency: EUROPEAN COMMISSION
Funding: 52000
Reference: EUROMENE_CA15111_COST2015
Duration: 21/04/2016 - 20/04/2020

Related news

The new therapeutic strategy aims at maintaining the efficacy of thalidomide while avoiding its main systemic adverse effects.

The event, held as part of World Lupus Day, incorporated the perspective of people living with the disease to address the challenges associated with lupus.

The global biopharmaceutical company UCB has acquired the data and clinical knowledge business of IMIDomics, a spin-off of the Vall d’Hebron Institute of Research (VHIR).

Related professionals

Victor Guerra Ruiz

Victor Guerra Ruiz

Predoctoral researcher
Pneumology
Read more
Anerkys Janett Uzcategui Sánchez

Anerkys Janett Uzcategui Sánchez

Gestió i Administració
Clinical Trials Economic Evaluation Unit
Commercial and Academic Clinical Research
Read more
Laura Gómez Dabó

Laura Gómez Dabó

Predoctoral researcher
Headache and Neurological Pain
Read more
Aleix Benítez Martínez

Aleix Benítez Martínez

Predoctoral researcher
Infectious Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.